In a recent legal development, a New York federal judge has ruled that Novartis must disclose certain privileged documents to Incyte, relating to the understanding of their contract for royalty payments from sales of Incyte’s blood cancer medication. This decision arises in the context of an upcoming trial addressing allegations of contract breach. The judge’s order stipulates that Novartis is obligated to produce these documents unless it chooses to prevent its former outside counsel, who was involved in negotiating the contract terms, from testifying on this topic during the trial.
As the case progresses, it underscores the intricate legal dynamics surrounding intellectual property and contract agreements in the pharmaceutical sector. For further details on the implications of this ruling, please visit the original article on Law360.